Vitamin D Deficiency Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Vitamin D Deficiency Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Vitamin D deficiency, or hypovitaminosis D, is due to lack or deficiency of fat-soluble vitamin D. Vitamin D plays an important role in calcium homeostasis and bone metabolism. It is most commonly seen in people who are not exposed to sunlight and have insufficient vitamin D in their diet. Some medications, including laxatives, steroids (prednisone), cholesterol-lowering drugs (cholestyramine and cholestipol), and anti-epileptics (phenobarbital and phenytoin), can also cause hypovitaminosis D. It can lead to osteomalacia in adults and rickets in children. It can cause muscle aches, joint deformities, weakness, and bone pain. It can be diagnosed with a vitamin D blood test. Fatty fish such as salmon, tuna, and mackerel; beef liver; cheese; mushrooms; and egg yolks are good sources of vitamin D. Vitamin D3 (cholecalciferol) supplementation has been shown to be more efficacious in achieving optimal 25-hydroxyvitamin D levels compared with vitamin D2 (ergocalciferol).
The Vitamin D Deficiency Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Vitamin D Deficiency Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vitamin D Deficiency Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Vitamin D Deficiency Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Vitamin D Deficiency Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Vitamin D Deficiency Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Vitamin D Deficiency Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
CANbridge Life Sciences LtdChangchun GeneScience Pharmaceutical Co Ltd
EPOK Therapeutics Inc
Genethon SA
Inozyme Pharma Inc
Kyowa Kirin Co Ltd
Panorama Research Institute
Ultragenyx Pharmaceutical Inc
University of Tennessee
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Vitamin D Deficiency Disorders reports